Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmaco-epidemiological Study on the Effect of Retacrit® on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation

NCT02158169 is registered in ClinicalTrials.gov with Hospira, now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT02158169
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02158169 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmaco-epidemiological Study on the Effect of Retacrit® on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Phase
Observational
Overall status
Completed
Start date
June 30, 2012
Completion date
December 31, 2014
Enrollment
2,167 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced anemia